Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Emvododstat · PTC299

Small molecule · Inhibitor of VEGFA mRNA 5' and 3' untranslated regions (VEGFA) · developed by PTC Therapeutics

Phase 2/3 Most advanced trial (none active)
PTCT Developer
1 Registered trials

What is Emvododstat?

Emvododstat (PTC299) is an orally bioavailable small molecule that inhibits VEGF synthesis by binding the 5' and 3' untranslated regions of VEGF mRNA, preventing its translation. It is studied in pneumonia and COVID-19.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PTC299
Drug type
Small molecule
Targets
VEGFA mRNA 5' and 3' untranslated regions (VEGFA)
Mechanism
Inhibitor of VEGFA mRNA 5' and 3' untranslated regions (VEGFA)
Pathways
angiogenesis, endothelial cell migration, proliferation and survival, tumor cell proliferation
Therapy area
Infectious disease, Respiratory
Developer
PTC Therapeutics (PTCT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2/3
UNII
053QD2I96A

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04439071 Phase 2/3 Pneumonia Terminated PTCT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

CoronavirusCOVID-19Pneumonia

Other drugs acting on VEGFA

More from PTC Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PTCT page.

Follow PTCT, the company behind Emvododstat

See PTCT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PTCT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.